Eversheds has advised CBPE Capital LLP, the mid-market private equity firm, on the sale of IDIS Group Holdings to Clinigen Group plc.

CBPE Capital LLP (CBPE), has sold IDIS Group Holdings (IDIS) to Clinigen Group plc (Clinigen), the AIM listed speciality pharmaceuticals and pharmaceuticals services business, for an Enterprise Value of £225m.

The transaction represents a money multiple of 22x CBPE’s £9.4m investment in Idis.

IDIS is the global leader in providing regulatory and ethically compliant access to unlicensed medicines for healthcare professionals and their patients with unmet medical needs.

The Eversheds team was led by Partner and head of private equity Richard Moulton, assisted by Principal Associate Louise Finnie and Associate Andy Lord. Share options advice was provided by Partner Danny Blum and Associate Richard Sharman.

Richard Moulton said:

“As the private equity industry becomes increasingly buoyant, we are pleased to have assisted CBPE on this significant deal which is in line with its overall strategy. We look forward to working with the team on future transactions.”

Sean Dinnen of CBPE said:

“The Eversheds team have provided first class support to CBPE throughout the period of our investment in Idis. The firm originated the opportunity for us, have given full service support to the IDIS group throughout our tenure and have done an excellent job in helping us successfully execute this transaction.”